Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Application drying time for oxybutynin chloride topical gel.

Newman DK, Olsen SM, Dahl NV.

Urol Nurs. 2012 Sep-Oct;32(5):265-9.

PMID:
23472531
2.

Adding to the evidence base: application drying time for oxybutynin chloride topical gel.

Sublett CM.

Urol Nurs. 2012 Sep-Oct;32(5):270-1. No abstract available.

PMID:
23472532
3.

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.

J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.

PMID:
19233423
4.

Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.

Dmochowski RR, Newman DK, Sand PK, Rudy DC, Caramelli KE, Thomas H, Hoel G.

Clin Drug Investig. 2011;31(8):559-571. doi: 10.2165/11588990-000000000-00000.

PMID:
21721591
5.

Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.

Sand PK, Davila GW, Lucente VR, Thomas H, Caramelli KE, Hoel G.

Am J Obstet Gynecol. 2012 Feb;206(2):168.e1-6. doi: 10.1016/j.ajog.2011.08.005. Epub 2011 Aug 11.

PMID:
21963104
6.

Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.

Staskin DR, Robinson D.

Expert Opin Pharmacother. 2009 Dec;10(18):3103-11. doi: 10.1517/14656560903451682. Review.

PMID:
19954278
7.

The evolution of transdermal therapy for overactive bladder.

Sand PK.

Curr Urol Rep. 2009 Sep;10(5):338-41.

PMID:
19709479
8.

Oxybutynin topical and transdermal formulations: an update.

Staskin DR, Salvatore S.

Drugs Today (Barc). 2010 Jun;46(6):417-25. doi: 10.1358/dot.2010.46.6.1487750. Review.

PMID:
20571610
9.

Transdermal drug delivery treatment for overactive bladder.

Dmochowski RR, Starkman JS, Davila GW.

Int Braz J Urol. 2006 Sep-Oct;32(5):513-20. Review.

10.

Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.

Cornel EB.

Eur Urol. 2007 Jul;52(1):286-7; author reply 287. Epub 2007 Apr 9. No abstract available.

PMID:
17434252
11.

Oxybutynin gel for the treatment of overactive bladder.

Gomelsky A, Dmochowski RR.

Expert Opin Pharmacother. 2012 Jun;13(9):1337-43. doi: 10.1517/14656566.2012.688953. Review.

PMID:
22607010
12.

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.

J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29.

PMID:
20303119
13.

Urinary incontinence: oxybutynin topical gel for overactive bladder.

Chapple CR.

Nat Rev Urol. 2009 Jul;6(7):351-2. doi: 10.1038/nrurol.2009.111. No abstract available.

PMID:
19578347
14.

Transdermal oxybutynin for overactive bladder.

Davila GW, Starkman JS, Dmochowski RR.

Urol Clin North Am. 2006 Nov;33(4):455-63, viii.

PMID:
17011381
15.

Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.

Yoo DS, Han JY, Lee KS, Choo MS.

Int J Clin Pract. 2012 Feb;66(2):132-8. doi: 10.1111/j.1742-1241.2011.02838.x. Epub 2011 Dec 20. Erratum in: Int J Clin Pract. 2012 Jun;66(6):611.

PMID:
22188444
16.

Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

Kennelly MJ, Lemack GE, Foote JE, Trop CS.

Urology. 2009 Oct;74(4):741-5. doi: 10.1016/j.urology.2009.05.008. Epub 2009 Jul 22.

PMID:
19628264
17.

Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.

Herschorn S, Vicente C, Piwko C.

J Med Econ. 2010;13(3):508-15. doi: 10.3111/13696998.2010.509244.

PMID:
20690893
18.

Topical oxybutynin (Gelnique) for overactive bladder.

[No authors listed]

Med Lett Drugs Ther. 2010 Feb 8;52(1331):10-1. Review. No abstract available.

PMID:
20216524
19.

Gelnique (oxybutynin chloride) 10% gel for overactive bladder.

Lajiness MJ.

Urol Nurs. 2010 Jul-Aug;30(4):253-4.

PMID:
20949812
20.

Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.

Fader M, Glickman S, Haggar V, Barton R, Brooks R, Malone-Lee J.

J Urol. 2007 Jan;177(1):208-13; discussion 213.

PMID:
17162046

Supplemental Content

Support Center